India Seeks 60-Day Probe Into Denial Of Drug Sales To Retail Chains
This article was originally published in PharmAsia News
An Indian government agency has begun a preliminary investigation into whether some drug makers are refusing to sell directly to large corporate retail chains. The Monopolies and Restrictive Trade Practices Commission requested the Director General Of Investigation and Registration look into the allegations and report back in 60 days. Allegedly responsible are drug wholesalers and drug makers Lupin, Maneeah Pharma and Sandoz, said to have discusses selling only to the group's members. (Click here for more
You may also be interested in...
FDA's COVID-19 Naughty List Now Includes Marketers Of Copper Germ Stoppers, ‘24-Hour’ Hand Sanitizer
Warning letters issued by the US FDA on 28 May target two companies using COVID-19 and other disease-prevention claims to market purported germ-killing products, including a rub touted as 24-hour protection and a line of copper rollers and other implements to disinfect hands and personal items.
Industry-funded survey by Charles River Associates explores diverse perceptions about pricing for high-cost cell treatments – including curative cell and gene therapy – among various stakeholder groups.
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.